Kodiak’s Phase 3 eye drug success; Innate discontinues anti-CD20 program

Kodiak Sciences Reports Positive Phase 3 GLOW2 Results for Zenkuda in Diabetic Retinopathy

Kodiak Sciences announced positive topline results from its GLOW2 phase 3 superiority study evaluating Zenkuda (tarcocimab tedromer) in patients with diabetic retinopathy (DR). Zenkuda is an investigational anti-vascular endothelial growth factor (VEGF) intravitreal biologic developed using Kodiak’s proprietary antibody biopolymer conjugate (ABC) platform, designed to enhance durability and reduce treatment burden. GLOW2 was a confirmatory phase…

Kodiak’s Phase 3 eye drug success; Innate discontinues anti-CD20 program

Plus, news about Astellas' setidegrasib and Anavex: 📈 Kodiak’s eye drug win: The biotech’s experimental drug Zenkuda, whose scientific name is tarcocimab tedromer, beat a sham procedure in patients ...